Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 529023Generated: October 31, 2026

(S)-3-((tert-butyldimethylsilyloxy)methyl)-1,2,3,4-tetrahydroisoquinoline → Methyl 3-((S)-3-((tert-butyldimethylsilyloxy)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4-(4-(dibutylcarbamoyl)-1-(3-(4-methylpiperazin-1-yl)propyl)-1H-imidazol-2-yl)benzoate

https://huagongshe.com/reaction/529023

Reaction equation

Participants

RoleNameHCIDCharge
Reactant(S)-3-((tert-butyldimethylsilyloxy)methyl)-1,2,3,4-tetrahydroisoquinolineHCID 10333747—
Reactant2-(4-(dibutylcarbamoyl)-1-(3-(4-methylpiperazin-1-yl)propyl)-1H-imidazol-2-yl)-5-(methoxycarbonyl)benzoic acidHCID 71060887—
ProductMethyl 3-((S)-3-((tert-butyldimethylsilyloxy)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4-(4-(dibutylcarbamoyl)-1-(3-(4-methylpiperazin-1-yl)propyl)-1H-imidazol-2-yl)benzoateHCID 8671894193.6%

Reaction Steps

Following a procedure analogous to that for the synthesis of Intermediate 271H, 2-(4-(dibutylcarbamoyl)-1-(3-(4-methylpiperazin-1-yl)propyl)-1H-imidazol-2-yl)-5-(methoxycarbonyl)benzoic acid (110 mg, 0.2 mmol) and (S)-3-((tert-butyldimethylsilyloxy)methyl)-1,2,3,4-tetrahydroisoquinoline (73 mg, 0.26 mmol) were converted to the title compound (150 mg, 93%). MS(ESI+) m/z 802.4 (M+H)+.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS09346795B2
Source datasetuspto-grants-2016_05
ORD IDord-bc27c585d3dc452ca26e258b40c31d27
Source noteuspto-grants-2016_05